
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is a promising stock with strong potential for growth due to its leading position in the life sciences tools and diagnostics market, as well as its strategic initiatives aimed at improving its business mix and efficiency. The upcoming acquisition of Wilson Wolf, a high-growth cell therapy tools company, is also expected to be a major catalyst for the company's growth. While the company's near-term outlook may be muted due to market conditions and regulatory risks, we believe its long-term growth prospects remain strong. With its strong financials and commitment to sustainability, Bio-Techne is well positioned to capitalize on the rebound of biotech funding and maintain its competitive edge in the market.
Bears say
Bio-Techne is facing several key risks that could negatively impact its stock, including potential delays in end market recovery, concerns about loss of market share to larger competitors in the research reagents space, potential disappointment in cell therapy progress which accounts for ~15% of the company's sales, and any potential issues with acquisitions or integration. The company has implemented sustainability measures, but there is no direct link between these metrics and executive compensation. There may also be concerns about potential disruption from AI and software technologies in the life science industry, but the company's track record in M&A gives some confidence in its ability to adapt to changing market conditions. Despite some positive developments in the recent quarter such as strong bookings for its COMET instrument and growth in its diagnostics business, there are still headwinds such as the cell therapy air pocket and the impact of an OEM order pull-forward, predicting flat organic growth for the next quarter. Overall, the outlook for Bio-Techne's stock is negative due to a combination of risks and uncertainties in the life sciences industry and the company's specific segment exposure.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares